UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination

Journal of hematology and oncology, 2022-06, Vol.15 (1), p.75-75, Article 75

2022

Volltextzugriff (PDF)

Rehabilitation in patients with lymphoma: An overview of Systematic Reviews

Journal of rehabilitation medicine, 2021-03, Vol.53 (3), p.jrm00163-jrm00163

2021

Volltextzugriff (PDF)

Health‐related quality of life for patients with chronic lymphocytic leukaemia – A critical outcome measure in the era of highly effective therapies

British journal of haematology, 2022-05, Vol.197 (4), p.394-396

2022

Volltextzugriff (PDF)

Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months

Blood advances, 2020-01, Vol.4 (1), p.165-173

2020

Volltextzugriff (PDF)

How I treat chronic lymphocytic leukemia after venetoclax

Blood, 2021-08, Vol.138 (5), p.361-369

2021

Volltextzugriff (PDF)

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Cancer discovery, 2019-03, Vol.9 (3), p.342-353

2019

Volltextzugriff (PDF)

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy

Blood, 2022-11, Vol.140 (20), p.2127-2141

2022

Volltextzugriff (PDF)

Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma

Leukemia & lymphoma, 2022-11, Vol.63 (13), p.3217-3221

2022

Volltextzugriff (PDF)

Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53 -mutated disease

Leukemia & lymphoma, 2023-11, Vol.64 (11), p.1792-1800

2023

Volltextzugriff (PDF)

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance

Blood advances, 2022-10, Vol.6 (20), p.5589-5592

2022

Volltextzugriff (PDF)

T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease

Bone marrow transplantation (Basingstoke), 2021-11, Vol.56 (11), p.2857-2859

2021

Volltextzugriff (PDF)

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition

Blood advances, 2021-10, Vol.5 (20), p.4054-4058

2021

Volltextzugriff (PDF)

Treatment approaches for patients with TP53-mutated mantle cell lymphoma

The Lancet. Haematology, 2023-02, Vol.10 (2), p.e142-e154

2023

Volltextzugriff (PDF)

Promises and pitfalls of targeted agents in chronic lymphocytic leukemia

Cancer Drug Resistance, 2020-01

2020

Volltextzugriff (PDF)

Chronic lymphocytic leukaemia Australasian consensus practice statement

Internal medicine journal, 2023-09, Vol.53 (9), p.1678-1691

2023

Volltextzugriff (PDF)

Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre

Internal medicine journal, 2022-07, Vol.52 (7), p.1286-1287

2022

Volltextzugriff (PDF)

A case of multi-drug resistant ESBL-producing Shigella sonnei acute acalculous cholecystitis and gastroenteritis in a returned traveller

Journal of travel medicine, 2018-08, Vol.25 (1)

2018

Volltextzugriff (PDF)

Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon

Blood advances, 2024-03, Vol.8 (6), p.1439-1443

2024

Volltextzugriff (PDF)

Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy

Leukemia & lymphoma, 2016-05, Vol.57 (5), p.1044-1053

2016

Volltextzugriff (PDF)

All is not lost - the improving outcome of patients with chronic lymphocytic leukaemia failing frontline therapy with fludarabine, cyclophosphamide and rituximab

European journal of haematology, 2013-08, Vol.91 (2), p.189-190

2013

Volltextzugriff (PDF)

Depletion of the Mitochondrial E3 Ligase MARCH5 Induces Synthetic Lethality to BCL2 Inhibitor (Venetoclax) Therapy in Cell Lines Representative of Diverse Blood Cancers

Blood, 2023-11, Vol.142 (Supplement 1), p.415-415

2023

Volltextzugriff (PDF)

BAX Mutated Clonal Hematopoiesis Arises Following Treatment with the BCL2 Inhibitor Class of Therapeutics across a Range of Hematological and Non-Hematological Neoplasms

Blood, 2023-11, Vol.142 (Supplement 1), p.2688-2688

2023

Volltextzugriff (PDF)

Early Bortezomib Failure Predicts Shorter PFS: a Retrospective Analysis from 4 Victorian Centres

Blood, 2016-12, Vol.128 (22), p.5708-5708

2016

Volltextzugriff (PDF)

Clinicopathological Features and Outcomes of Progression for Chronic Lymphocytic Leukaemia (CLL) Treated with the BCL2 Inhibitor Venetoclax

Blood, 2016-12, Vol.128 (22), p.3223-3223

2016

Volltextzugriff (PDF)

Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy

Leukemia & Lymphoma, 2016, Vol.57 (5), p.1044-1053

2016

Volltextzugriff (PDF)

1 – 25 von 143

Suche als RSS-Feed

Aktive Filter

ThemaMiddle Aged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(132)
Mit Volltextzugriff
(116)

Publikationsform

Sprache

Englisch
(143)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

Science & Technology
(95)
Life Sciences & Biomedicine
(79)
Humans
(54)
Animals
(30)
Biological And Medical Sciences
(26)
Male
(20)
Female
(19)
Medical Sciences
(19)
Mice
(17)
Hematology
(16)
Adult
(15)
Oncology
(13)
Immunology
(10)
Technology
(10)
General & Internal Medicine
(9)
Applied Sciences
(8)
Cell Biology
(8)
Exact Sciences And Technology
(8)
Fundamental And Applied Biological Sciences. Psychology
(8)
Mice, Inbred Nod
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination

Rehabilitation in patients with lymphoma: An overview of Systematic Reviews

Health‐related quality of life for patients with chronic lymphocytic leukaemia – A critical outcome measure in the era of highly effective therapies

Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months

How I treat chronic lymphocytic leukemia after venetoclax

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy

Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma

Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53 -mutated disease

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance

T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition

Treatment approaches for patients with TP53-mutated mantle cell lymphoma

Promises and pitfalls of targeted agents in chronic lymphocytic leukemia

Chronic lymphocytic leukaemia Australasian consensus practice statement

Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre

A case of multi-drug resistant ESBL-producing Shigella sonnei acute acalculous cholecystitis and gastroenteritis in a returned traveller

Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon

Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy

All is not lost - the improving outcome of patients with chronic lymphocytic leukaemia failing frontline therapy with fludarabine, cyclophosphamide and rituximab

Depletion of the Mitochondrial E3 Ligase MARCH5 Induces Synthetic Lethality to BCL2 Inhibitor (Venetoclax) Therapy in Cell Lines Representative of Diverse Blood Cancers

BAX Mutated Clonal Hematopoiesis Arises Following Treatment with the BCL2 Inhibitor Class of Therapeutics across a Range of Hematological and Non-Hematological Neoplasms

Early Bortezomib Failure Predicts Shorter PFS: a Retrospective Analysis from 4 Victorian Centres

Clinicopathological Features and Outcomes of Progression for Chronic Lymphocytic Leukaemia (CLL) Treated with the BCL2 Inhibitor Venetoclax

Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy

Aktive Filter

Suchergebnisse filtern